RE: Can't find any news?. $1.385 Billion Deal with.
Transitions Partner with AZD-103 has recently completed a $ 1.385 billion dollar deal with J&J that gives them $885 million cash for new shares. the other $500 million is slated for Bapineuzimab technology advancement.
Short story is that the next step in the AZD-103 Trial can now be performed without investors worrying that Elan has enough cash or not. seeing that they (elan) don't have to pay for Bap anymore.......
Consider the J&J/ELN deal and work out the value it put on an Alz technology with safety issues (Bap)........then compare that valuation to AZD-103 and the potential upcoming events. VOILA!